Juno Therapeutics Inc. (JUNO) 60.66 $JUNO
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 7.37 (-0.09), KITE: 57.68 (-2.30), CLDX: 27.87 (+0.03), JUNO: 60.66 (-0.09)
Juno Therapeutics (JUNO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:01AM CDT
Juno Therapeutics (JUNO) Shares March Higher, Can It Continue?
JUNO: 60.66 (-0.09)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 120.77 (-3.12), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
U.S. IPO Weekly Recap: SolarEdge Shines While Other IPOs Fall Flat
Renaissance Capital IPO Research - at Seeking Alpha - Sat Mar 28, 6:39AM CDT
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly...
SEDG: 21.93 (-0.14), ENPH: 13.19 (-0.03), TANH: 8.00 (+0.20), VRAY: (), FSB: 21.00 (unch), CLLS: 34.58 (-0.62), VLRX: (), JCAP: 20.75 (unch), JUNO: 60.66 (-0.09), PUMP: (), GDDY: ()
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 372.10 (-2.49), ZIOP: 10.77 (-0.84), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), INXN: 28.20 (+0.14), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), LEN: 51.81 (+0.32), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), XHB: 36.86 (+0.01), P: 16.21 (-0.18), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), PHM: 22.23 (-0.21), DIA: 177.58 (-1.81), ITB: 28.23 (-0.03), JUNO: 60.66 (-0.09), IWM: 124.37 (-0.40), KBH: 15.62 (-0.04), AAPL: 124.43 (-1.94), ZU: 12.99 (-0.38), BABA: 83.24 (-0.66)
Biotech Stock Selloff: Is It Justified?
at Investor's Business Daily - Thu Mar 26, 11:12AM CDT
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray's Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead...
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), KITE: 57.68 (-2.30), GILD: 98.13 (-2.56), ALXN: 173.30 (-6.96), JUNO: 60.66 (-0.09), CELG: 115.28 (-4.74)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), PFE: 34.79 (-0.21), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.77 (-0.84), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
Juno: Trying To Justify A $5.5B Valuation For A Year-Old Company
Kanak Kanti De - at Seeking Alpha - Tue Mar 24, 10:04AM CDT
JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro
at The Street - Mon Mar 23, 11:08AM CDT
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
ADXS: 14.44 (+1.00), JUNO: 60.66 (-0.09)
Confessions of a Value Investor Stuck in a High-Growth Industry
Brian Orelli, The Motley Fool - Motley Fool - Sun Mar 22, 7:01AM CDT
I'm a cheapskate. I'll buy a year's worth of ketchup when it's on sale, doing the discounted cash flow in my head to make sure the savings covers the lost interest. With rates as low as they've been, it's not that hard. I should be a value...
JNJ: 100.60 (-0.95), VRTX: 117.97 (-3.28), PCYC: 255.95 (-0.48), JUNO: 60.66 (-0.09), ABBV: 58.54 (+0.30), MNKD: 5.20 (-0.13)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 120.77 (-3.12), QURE: 24.32 (-0.85), SGMO: 15.68 (-0.18), JUNO: 60.66 (-0.09), ATHX: 2.88 (+0.02), NVS: 98.61 (-2.70)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), OVAS: 34.73 (-3.45), RGLS: 16.94 (-0.32), CTIC: 1.81 (-0.06), CELG: 115.28 (-4.74), BLCM: 23.17 (+0.52), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), RCPT: 164.89 (+4.84), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Prothena Soars On Parkinson's Drug; Biogen In Focus
at Investor's Business Daily - Thu Mar 19, 8:21PM CDT
Prothena Corp. (PRTA) late Thursday reported clinical data showing that its new immunotherapy reduces a key protein linked to the disease, sending shares sharply higher in after-hours action. PRX002, a monoclonal antibody, safely reduced free serum...
BIIB: 422.24 (-9.38), KITE: 57.68 (-2.30), JUNO: 60.66 (-0.09), PRTA: 38.14 (-1.23)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 120.77 (-3.12), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Why Juno Therapeutics Inc is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 19, 12:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Juno Therapeutics, What: Shares...
JUNO: 60.66 (-0.09)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 120.77 (-3.12), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), CNDO: 3.85 (+0.31), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), AMGN: 159.85 (-4.45), LBIO: 12.11 (+0.49), JUNO: 60.66 (-0.09), LLY: 72.65 (-1.22), GSK: 46.15 (-1.05), NVS: 98.61 (-2.70), CELGZ: 2.97 (+0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:47AM CDT
APPS: 3.26 (-0.02), RMGN: 1.26 (-0.11), GOMO: 3.78 (-0.06), MILL: 0.63 (-0.12), HIIQ: 7.81 (-0.06), DGSE: 1.49 (-0.07), VNCE: 18.55 (+1.20), BIOC: 2.24 (-0.10), GBR: 2.01 (-0.13), GES: 18.59 (-0.30), SFY: 2.16 (+0.01), CNDO: 3.85 (+0.31), BTX: 4.97 (-0.03), JUNO: 60.66 (-0.09), MTOR: 12.61 (+0.21), VBLT: 5.20 (-0.09), WHLR: 2.29 (-0.03), CMLS: 2.47 (-0.05), AMCO: 1.14 (-0.16), FOLD: 10.88 (-0.09)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 7.37 (-0.09), KITE: 57.68 (-2.30), CLDX: 27.87 (+0.03), JUNO: 60.66 (-0.09)
Juno Therapeutics (JUNO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:01AM CDT
Juno Therapeutics (JUNO) Shares March Higher, Can It Continue?
JUNO: 60.66 (-0.09)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 120.77 (-3.12), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
U.S. IPO Weekly Recap: SolarEdge Shines While Other IPOs Fall Flat
Renaissance Capital IPO Research - at Seeking Alpha - Sat Mar 28, 6:39AM CDT
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly...
SEDG: 21.93 (-0.14), ENPH: 13.19 (-0.03), TANH: 8.00 (+0.20), VRAY: (), FSB: 21.00 (unch), CLLS: 34.58 (-0.62), VLRX: (), JCAP: 20.75 (unch), JUNO: 60.66 (-0.09), PUMP: (), GDDY: ()
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 372.10 (-2.49), ZIOP: 10.77 (-0.84), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), INXN: 28.20 (+0.14), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), LEN: 51.81 (+0.32), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), XHB: 36.86 (+0.01), P: 16.21 (-0.18), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), PHM: 22.23 (-0.21), DIA: 177.58 (-1.81), ITB: 28.23 (-0.03), JUNO: 60.66 (-0.09), IWM: 124.37 (-0.40), KBH: 15.62 (-0.04), AAPL: 124.43 (-1.94), ZU: 12.99 (-0.38), BABA: 83.24 (-0.66)
Biotech Stock Selloff: Is It Justified?
at Investor's Business Daily - Thu Mar 26, 11:12AM CDT
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray's Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead...
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), KITE: 57.68 (-2.30), GILD: 98.13 (-2.56), ALXN: 173.30 (-6.96), JUNO: 60.66 (-0.09), CELG: 115.28 (-4.74)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), PFE: 34.79 (-0.21), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.77 (-0.84), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
Juno: Trying To Justify A $5.5B Valuation For A Year-Old Company
Kanak Kanti De - at Seeking Alpha - Tue Mar 24, 10:04AM CDT
JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro
at The Street - Mon Mar 23, 11:08AM CDT
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
ADXS: 14.44 (+1.00), JUNO: 60.66 (-0.09)
Confessions of a Value Investor Stuck in a High-Growth Industry
Brian Orelli, The Motley Fool - Motley Fool - Sun Mar 22, 7:01AM CDT
I'm a cheapskate. I'll buy a year's worth of ketchup when it's on sale, doing the discounted cash flow in my head to make sure the savings covers the lost interest. With rates as low as they've been, it's not that hard. I should be a value...
JNJ: 100.60 (-0.95), VRTX: 117.97 (-3.28), PCYC: 255.95 (-0.48), JUNO: 60.66 (-0.09), ABBV: 58.54 (+0.30), MNKD: 5.20 (-0.13)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 120.77 (-3.12), QURE: 24.32 (-0.85), SGMO: 15.68 (-0.18), JUNO: 60.66 (-0.09), ATHX: 2.88 (+0.02), NVS: 98.61 (-2.70)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), OVAS: 34.73 (-3.45), RGLS: 16.94 (-0.32), CTIC: 1.81 (-0.06), CELG: 115.28 (-4.74), BLCM: 23.17 (+0.52), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), RCPT: 164.89 (+4.84), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Prothena Soars On Parkinson's Drug; Biogen In Focus
at Investor's Business Daily - Thu Mar 19, 8:21PM CDT
Prothena Corp. (PRTA) late Thursday reported clinical data showing that its new immunotherapy reduces a key protein linked to the disease, sending shares sharply higher in after-hours action. PRX002, a monoclonal antibody, safely reduced free serum...
BIIB: 422.24 (-9.38), KITE: 57.68 (-2.30), JUNO: 60.66 (-0.09), PRTA: 38.14 (-1.23)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 120.77 (-3.12), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Why Juno Therapeutics Inc is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 19, 12:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Juno Therapeutics, What: Shares...
JUNO: 60.66 (-0.09)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 120.77 (-3.12), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), CNDO: 3.85 (+0.31), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), AMGN: 159.85 (-4.45), LBIO: 12.11 (+0.49), JUNO: 60.66 (-0.09), LLY: 72.65 (-1.22), GSK: 46.15 (-1.05), NVS: 98.61 (-2.70), CELGZ: 2.97 (+0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:47AM CDT
APPS: 3.26 (-0.02), RMGN: 1.26 (-0.11), GOMO: 3.78 (-0.06), MILL: 0.63 (-0.12), HIIQ: 7.81 (-0.06), DGSE: 1.49 (-0.07), VNCE: 18.55 (+1.20), BIOC: 2.24 (-0.10), GBR: 2.01 (-0.13), GES: 18.59 (-0.30), SFY: 2.16 (+0.01), CNDO: 3.85 (+0.31), BTX: 4.97 (-0.03), JUNO: 60.66 (-0.09), MTOR: 12.61 (+0.21), VBLT: 5.20 (-0.09), WHLR: 2.29 (-0.03), CMLS: 2.47 (-0.05), AMCO: 1.14 (-0.16), FOLD: 10.88 (-0.09)
